Innovative drugs based on Prostaglandins & Nitric Oxide

Who we are

Gurus BioPharm is a global leader in the development of innovative drugs based on prostaglandin modification by Nitric Oxide donor.

Our technology

Our Prostaglandin & Nitric Oxide research platform binds two regulatory molecules with unique properties - prostaglandins and nitric oxide. As a result, we get multi-target (not single-target) first-in-class innovative drugs with remarkable biological activity and an excellent safety profile.

Pipeline

First-in-class

GUR-701 (Alopecia)

GUR-701 novel drug candidate passed clinical proof of concept (PoC). It is registered as functional cosmetics, 3000+ patients are using it. The product shows amazing results and has a prospect to be #1 alopecia treatment therapy globally.

First-in-class

GUR-501 (Asthma / COPD)

GUR-501 innovative drug candidate can be the only effective therapy for chronic patients with Asthma / COPD.

First-in-class

GUR-1001 (Glaucoma / retina ischemia)

GUR-1001 novel drug candidate can be the only glaucoma treatment medication that also cures retina ischemia.

First-in-class

GUR-602 (Critical Limb Ischemia / PAD)

GUR-602 innovative drug candidate simultaneously acts to several targets to restore severe damage of peripheral arteries.